Overview

Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
To determine if Alvimopan during open or robotic radical cystectomy with urinary diversion results in quicker return of bowel function (GI-2 recovery = time to upper [first toleration of solid food] and lower [first bowel movement] gastrointestinal recovery) compared to placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Brigham and Women's Hospital
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Alvimopan